Incyte Corp (INCY)

Nov 24, 2025

Incyte (INCY): Barclays Raises Price Target to $115, Maintains Overweight Rating | INCY Stock News - GuruFocus

Nov 24, 2025

Nov 23, 2025

Does Incyte's Expanding Drug Pipeline Signal an Opportunity Following a 46.8% Price Surge? - Yahoo Finance UK

Nov 23, 2025

Nov 22, 2025

Incyte (INCY) Tops Goldman Sachs' Hedge Fund Concentration List - GuruFocus

Nov 22, 2025

Nov 21, 2025

Officer Tray Files To Sell 169 Of Incyte Corp [INCY] - TradingView

Nov 21, 2025

Nov 21, 2025

Commit To Purchase Incyte At $87.50, Earn 12.3% Annualized Using Options - Nasdaq

Nov 21, 2025

Nov 20, 2025

Is Incyte Corporation (ICY) stock among top earnings playsJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com

Nov 20, 2025

Nov 20, 2025

Incyte to Present at Upcoming December 2025 Investor Conferences - BioSpace

Nov 20, 2025

Nov 19, 2025

Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛

Nov 19, 2025

Nov 19, 2025

Is Incyte Corporation (ICY) stock considered safe havenJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - newser.com

Nov 19, 2025

Nov 19, 2025

Incyte to Present at Upcoming Investor Conferences - Yahoo Finance

Nov 19, 2025

Nov 18, 2025

Incyte at Jefferies London: Strategic Shift to Diversification - Investing.com

Nov 18, 2025

Nov 17, 2025

Incyte Expands ‘Moments of Clarity’ With New Stories Spotlighting Chronic Skin Conditions - MyChesCo

Nov 17, 2025

Nov 17, 2025

Incyte Stock Outlook: Is Wall Street Bullish or Bearish? - MSN

Nov 17, 2025

Nov 17, 2025

VP Denton Files To Sell 278 Of Incyte Corp [INCY] - TradingView

Nov 17, 2025

Nov 17, 2025

Is Incyte Corporation building a consolidation baseEarnings Recap Report & Verified Chart Pattern Signals - newser.com

Nov 17, 2025

Nov 17, 2025

Incyte (INCY) Receives Positive Opinion for Minjuvi in Europe - GuruFocus

Nov 17, 2025

Nov 17, 2025

Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL) - BioSpace

Nov 17, 2025

Nov 16, 2025

Incyte corp EVP Steven Stein sells shares worth $897,866 - MSN

Nov 16, 2025

Nov 15, 2025

Can Incyte Corporation (ICY) stock attract analyst upgradesEarnings Trend Report & Reliable Entry Point Trade Alerts - newser.com

Nov 15, 2025

Nov 15, 2025

Forecasting Incyte Corporation price range with options dataJuly 2025 Outlook & Fast Entry High Yield Tips - newser.com

Nov 15, 2025

Nov 14, 2025

STATE STREET CORP Reduces Stake in Incyte Corp: A Strategic Port - GuruFocus

Nov 14, 2025

Nov 14, 2025

What risks investors should watch in Incyte Corporation stockTreasury Yields & AI Powered Market Entry Ideas - newser.com

Nov 14, 2025

Nov 14, 2025

Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch

Nov 14, 2025

Nov 14, 2025

Incyte Corp. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛

Nov 14, 2025

Nov 14, 2025

Key metrics from Incyte Corporation’s quarterly dataJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com

Nov 14, 2025

Nov 13, 2025

Why Analysts See Incyte’s Story Shifting as Pipeline Progress Drives New Valuation Targets - Yahoo Finance

Nov 13, 2025

Nov 13, 2025

Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 13, 2025

Nov 13, 2025

Will Incyte Corporation stock see PE expansionQuarterly Growth Report & Weekly High Return Opportunities - newser.com

Nov 13, 2025

Nov 13, 2025

Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch

Nov 13, 2025

Nov 13, 2025

Incyte Prepares to Showcase Pipeline Momentum With New mutCALR Data at ASH 2025 - MyChesCo

Nov 13, 2025

Nov 13, 2025

Incyte (INCY): Exploring Valuation After Recent Share Price Rally and Pipeline Progress - Yahoo Finance

Nov 13, 2025

Nov 12, 2025

Incyte stock hits 52-week high at 108.81 USD By Investing.com - Investing.com Canada

Nov 12, 2025

Nov 12, 2025

Incyte stock hits 52-week high at 108.81 USD - Investing.com

Nov 12, 2025

Nov 12, 2025

Peering Into Incyte Corp's Recent Short Interest - Benzinga

Nov 12, 2025

Nov 11, 2025

Incyte Posts 20% Revenue Growth, Raises 2025 Outlook on Strong Drug Demand - MSN

Nov 11, 2025

Nov 11, 2025

Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

Nov 11, 2025

Nov 11, 2025

Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus - MyChesCo

Nov 11, 2025

Nov 11, 2025

The Bull Case For Incyte (INCY) Could Change Following Raised 2025 Guidance and Oncology Program Updates – Learn Why - simplywall.st

Nov 11, 2025

Nov 11, 2025

Prelude Strikes $910 Million Deal With Incyte for Groundbreaking JAK2 Cancer Therapy - MyChesCo

Nov 11, 2025

Nov 11, 2025

Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains - 富途牛牛

Nov 11, 2025

Nov 10, 2025

Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack - Yahoo Finance

Nov 10, 2025

Nov 10, 2025

Incyte at Guggenheim Conference: Strategic Focus on Innovation - Investing.com

Nov 10, 2025

Nov 10, 2025

Can Incyte Corporation stock hit record highs again2025 Performance Recap & Real-Time Volume Analysis - newser.com

Nov 10, 2025

Nov 10, 2025

Published on: 2025-11-10 05:29:16 - newser.com

Nov 10, 2025

Nov 10, 2025

Can Incyte Corporation stock deliver sustainable ROEMarket Growth Report & Reliable Price Action Trade Plans - newser.com

Nov 10, 2025

Nov 09, 2025

Incyte and Enable Injections Join Forces to Advance At-Home Cancer Treatments - MyChesCo

Nov 09, 2025

Nov 09, 2025

Incyte to Highlight Innovation at Major Global Healthcare Conferences in November - MyChesCo

Nov 09, 2025

Nov 08, 2025

Prelude Therapeutics (PRLD): Valuation Snapshot Following Incyte Deal and Pipeline Realignment - Yahoo Finance

Nov 08, 2025

Nov 07, 2025

Will Incyte Corporation stock outperform Dow Jones indexBull Run & Weekly High Momentum Picks - newser.com

Nov 07, 2025

Nov 07, 2025

How Incyte Corporation stock responds to policy changesWeekly Trend Report & Smart Money Movement Alerts - newser.com

Nov 07, 2025

Nov 07, 2025

Incyte boosts annual sales forecast of blood cancer drug after strong quarter - MSN

Nov 07, 2025

Nov 07, 2025

Incyte Insider Sold Shares Worth $534,813, According to a Recent SEC Filing - MarketScreener

Nov 07, 2025

Nov 06, 2025

Incyte EVP Denton sells $60,613 in stock By Investing.com - Investing.com South Africa

Nov 06, 2025

Nov 06, 2025

Incyte EVP Denton sells $60,613 in stock - Investing.com India

Nov 06, 2025